COVID-19, Latent tuberculosis, Coinfection, Trained immunity
SARS-CoV-2 variants, humoral immunity, mixed-vaccine study, neutralizing activity, delta, JN.1, psuedotyped-viral particles, high infectious disease burden population
human coronaviruses, NL63, OC43, SARS-CoV-2, COVID-19 vaccinations, preexisting immunity
ELISPOT, CD19+ B cells, Tuberculosis, Plasmablasts, Lymphocyte